Type 2 Gaucher disease: 15 new cases and review of the literature
- PMID: 16485335
- DOI: 10.1016/j.braindev.2005.04.005
Type 2 Gaucher disease: 15 new cases and review of the literature
Abstract
Objectives: To provide a description of type 2 Gaucher disease. To attempt to define type 2 Gaucher disease within the spectrum of early-onset neuronopathic Gaucher disease.
Background: Type 2 Gaucher disease is a rare disorder due to glucocerebrosidase deficiency that comprises a rapidly progressing neurological degeneration associated with visceral signs. Most data collected rely on the description of single cases or siblings. Cases of perinatal-lethal Gaucher disease are frequently considered as type 2 Gaucher patients, though the clinical presentation is different.
Methods: We retrospectively studied the clinical history of 15 original acute Gaucher disease patients and reviewed the available data of 104 published cases of early-onset neuronopathic Gaucher disease, including 61 patients with the acute type and 43 cases of the perinatal-lethal form.
Results: The neurological presentation of type 2 Gaucher disease is homogeneous and characterized by precocious, severe, and rapidly progressive brainstem degeneration in the foreground. The most frequent initial signs are hyperextension of the neck, swallowing impairment, and strabismus. Provoked asphyxic episodes generally appear in a second time. They are followed by prolonged spontaneous apneas that seem to be the main pejorative feature. Other neurological signs may be observed, but epilepsy, myoclonic epilepsy/myoclonus, trismus, stridor, and progressive microcephaly are less characteristic. Psychomotor regression may occur, but is not a typical feature of the disease onset. Chronic or subacute pulmonary disease predominates in the visceral involvement. Hepatosplenomegaly, failure to thrive, thrombocytopenia, and anemia are the other remarkable, albeit non-specific, features. The inflammatory component of Gaucher disease is underlined by the addition of unexplained fever to this systemic clinical picture. The natural history and particular signs of perinatal-lethal Gaucher disease do not belong to the type 2 Gaucher disease phenotype.
Conclusion: Type 2 Gaucher disease is a clinically homogeneous entity. The specificity of the neurological involvement is sufficient to suspect the diagnosis at the onset of the disease. Type 2 and perinatal-lethal Gaucher diseases are easily distinguishable in most cases.
Similar articles
-
Perinatal-lethal Gaucher disease.Am J Med Genet A. 2003 Jul 30;120A(3):338-44. doi: 10.1002/ajmg.a.20117. Am J Med Genet A. 2003. PMID: 12838552
-
Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.Eur J Pediatr. 2004 Feb;163(2):58-66. doi: 10.1007/s00431-003-1362-0. Epub 2003 Dec 16. Eur J Pediatr. 2004. PMID: 14677061 Review.
-
[Clinical aspects of early-stage neurological forms of Gaucher disease].Rev Med Interne. 2006 Mar;27 Suppl 1:S14-7. doi: 10.1016/s0248-8663(06)80005-6. Rev Med Interne. 2006. PMID: 16644395 French.
-
Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.Blood Cells Mol Dis. 2007 May-Jun;38(3):287-93. doi: 10.1016/j.bcmd.2006.11.003. Epub 2006 Dec 29. Blood Cells Mol Dis. 2007. PMID: 17196853 Review.
-
Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.Pediatr Res. 2003 Mar;53(3):387-95. doi: 10.1203/01.PDR.0000049515.79882.94. Pediatr Res. 2003. PMID: 12595585
Cited by
-
Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies.Front Pharmacol. 2024 Feb 13;15:1335058. doi: 10.3389/fphar.2024.1335058. eCollection 2024. Front Pharmacol. 2024. PMID: 38414738 Free PMC article. Review.
-
The psychosocial impact of childhood dementia on children and their parents: a systematic review.Orphanet J Rare Dis. 2023 Sep 7;18(1):277. doi: 10.1186/s13023-023-02859-3. Orphanet J Rare Dis. 2023. PMID: 37679855 Free PMC article.
-
Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases.Biomedicines. 2023 Apr 1;11(4):1067. doi: 10.3390/biomedicines11041067. Biomedicines. 2023. PMID: 37189685 Free PMC article. Review.
-
Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.Int J Mol Sci. 2022 Nov 18;23(22):14340. doi: 10.3390/ijms232214340. Int J Mol Sci. 2022. PMID: 36430817 Free PMC article. Review.
-
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.Front Mol Neurosci. 2022 Aug 3;15:934820. doi: 10.3389/fnmol.2022.934820. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35992201 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
